Asset Planning Services Inc. LA ADV Decreases Position in Pfizer Inc. $PFE

Asset Planning Services Inc. LA ADV reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,630 shares of the biopharmaceutical company’s stock after selling 1,450 shares during the period. Pfizer accounts for about 1.2% of Asset Planning Services Inc. LA ADV’s portfolio, making the stock its 23rd largest holding. Asset Planning Services Inc. LA ADV’s holdings in Pfizer were worth $2,657,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Trust Co of the South boosted its holdings in shares of Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 441 shares during the last quarter. Charter Oak Capital Management LLC grew its position in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 444 shares in the last quarter. Ballentine Partners LLC increased its holdings in shares of Pfizer by 0.5% in the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the last quarter. Finally, Members Trust Co lifted its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 467 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $27.37 on Monday. The firm has a 50-day simple moving average of $24.67 and a two-hundred day simple moving average of $24.12. The stock has a market cap of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company posted $0.60 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.